Indian Journal of Endocrine Surgery and Research

Register      Login

VOLUME 16 , ISSUE 1 ( Jan-Jun, 2021 ) > List of Articles

CASE REPORT

Multiple Endocrine Neoplasia 2A with Late-onset Medullary Carcinoma Thyroid and Bilateral Pheochromocytoma: A Complex Presentation

Smitha S Rao, Zahir Hussain, Shikhil Puzhakkal

Keywords : Endocrine, Endocrine cancer, Medullary carcinoma, Multiple endocrine neoplasia, Pheochromocytoma, Thyroid cancer

Citation Information : Rao SS, Hussain Z, Puzhakkal S. Multiple Endocrine Neoplasia 2A with Late-onset Medullary Carcinoma Thyroid and Bilateral Pheochromocytoma: A Complex Presentation. 2021; 16 (1):41-45.

DOI: 10.5005/jp-journals-10088-11155

License: CC BY-NC 4.0

Published Online: 26-08-2021

Copyright Statement:  Copyright © 2021; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Medullary carcinoma thyroids (MTCs) are rare malignancies of the thyroid gland, which arise from the parafollicular C-cells. They account for 5% of thyroid malignancies. The index case presented to us with bilateral pheochromocytomas and MTC. The family treated by us included the index case of MEN2A who underwent bilateral adrenalectomy and total thyroidectomy with central compartment neck dissection, his father with MTC treated with thyroid surgery and brother with a solitary nodule thyroid under evaluation. Father succumbed to the disease 8 months later. Surgery is the primary treatment in MTC with genetic testing, contributing to early diagnosis and treatment. MTC with MEN2A is a rare entity, with our case presenting in the third decade with no metastases. Diagnosis of MEN2A involves the complex biochemical workup followed by adrenal surgery before thyroidectomy. A poor understanding would lead to major catastrophe. Hence, there is a need to report this rare occurrence in a family.


PDF Share
  1. Priya R, Virmani N, Dabholkar JP. Medullary carcinoma of thyroid: case report and a review of literature. J Head Neck Physicians Surg 2016;4(2):80–84. DOI: 10.4103/2347-8128.196232.
  2. Kushchayev SV, Kushchayeva YS, Tella SH, et al. Medullary thyroid carcinoma – an update on imaging. Hindawi J Thyroid Res 2019;1–8. DOI: 10.1155/2019/1893047.
  3. Priya SR, Dravid CS, Digumarti R, et al. Targeted therapy for medullary thyroid cancer: a review. Front Oncol 2017;7:238. DOI: 10.3389/fonc.2017.00238.
  4. Nguyen L, Niccoli-Sire P, Caron P, et al. Pheochromocytoma in MEN2. Eur J Endocrinol 2001;144(1):37. DOI: 10.1530/eje.0.1440037.
  5. Desai SS, Sarkar S, Borges AM. A study of histopathological features of medullary carcinoma of the thyroid: cases from a single institute in India. Indian J Cancer 2005;42(1):25–29. DOI: 10.4103/0019-509X.15096.
  6. Venkataramana CG, Pai RR, Rao R, et al. Clinicopathological study of medullary carcinoma of thyroid: a single institute experience. Thyroid Res Pract 2018;15(1):38–41. DOI: 10.4103/trp.trp_43_17.
  7. Gomes AC, Silvestre C, Marçalo J, et al. Medullary thyroid carcinoma and pheochromocytoma in multiple endocrine neoplasia type 2A – a reversed order diagnosis. Endocrine Abstracts 2017;49:EP157. DOI: 10.1530/endoabs.49.EP157.
  8. Prabhu M, Shakya S, Ballal S, et al. Long-term clinicopathological feature of a family with multiple endocrine neoplasia type 2A caused by C634R RET gene mutation. Indian J Nucl Med 2020;35(1):48–53. DOI: 10.4103/ijnm.IJNM_168_19.
  9. Meijer JA, Bakker LE, Valk GD, et al. Radioactive iodine in the treatment of medullary thyroid carcinoma: a controlled multicenter study. Eur J Endocrinol 2013;168(5):779–786. DOI: 10.1530/EJE-12-0943.
  10. Almeida MQ, Hoff AO. Recent advances in the molecular pathogenesis and targeted therapies of medullary thyroid carcinoma. Curr Opin Oncol 2012;24(3):229–234. DOI: 10.1097/CCO.0b013e328351c71a.
  11. Machens A, Hofmann C, Hauptmann S, et al. Locoregional recurrence and death from medullary thyroid carcinoma in a contemporaneous series: 5-year results. Eur J Endocrinol 2007;157(1):85–93. DOI: 10.1530/EJE-07-0095.
  12. Wells SA, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 2015;25(6):579–581. DOI: 10.1089/thy.2014.0335.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.